EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

Xiaoying Zhao iD, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu-Qian Zhang, Cathy O'Brien, Gary J Doherty, Allen C Chen, KyoungSoo Lim, Song Ren, Peiming Ma und 1 weitere

British Journal of Clinical Pharmacology · 2026-03 · 92 (3) · 980-996

DOI: 10.1002/bcp.70287 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 12.11.2025. Verfasst von Xiaoying Zhao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Development Science, R&D China, AstraZeneca, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients with resectable NSCLC.

Methods

The durvalumab PopPK model was updated by integrating PK data from the AEGEAN study. Individual exposure metrics were derived from empirical Bayes estimates for ER analyses relating to safety (adverse events [AEs]) and efficacy (pathological complete response [pCR] and event‐free survival [EFS]).

Results

A two‐compartment model with a time‐dependent clearance adequately characterized durvalumab PK data. The typical parameter estimates clearance, central and peripheral volume of distribution were 0.285 L/day (relative standard error: 1.68%), 3.42 L (0.962%) and 2.30 L (2.09%), respectively. All identified covariates caused ≤21% of change on durvalumab PK parameters, indicating no meaningful impact on durvalumab exposure. At the plateaued dose level of durvalumab 1500 mg, a flat relationship was observed between durvalumab PK exposure and EFS, confirmed by Cox proportional hazards analysis, and pCR, confirmed by logistic regression analysis. Logistic regression analysis indicated that no clinically relevant relationships were observed between durvalumab PK exposure and safety endpoints, including grade ≥3 treatment‐related AEs, grade ≥3 treatment‐related AEs of special interest, and AEs leading to treatment discontinuation.

Conclusions

These results support the novel perioperative durvalumab regimen for patients with resectable NSCLC from the AEGEAN study, and no dose adjustment is necessary based on the PopPK and ER analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsModels, BiologicalAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedAgedNeoplasm StagingAdultNeoadjuvant TherapyBayes Theorem

Stichwörter der Autor:innen

anticancer drugsclinical trialsimmunotherapypharmacokineticspopulation analysis

Substanzen

durvalumabAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Clinical Pharmacology, Development Science, R&D China, AstraZeneca, Shanghai, China.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Late Oncology R&D, AstraZeneca, Cambridge, UK.
  • Late Oncology R&D, AstraZeneca, New York, NY, USA.

ORCID-Profile: Xiaoying Zhao, Diansong Zhou

Zitieren

APA

Zhao, X., Ding, J., Zhao, J., Zhang, L., Abegesah, A., Zhang, Y. Q., O'Brien, C., Doherty, G. J., Chen, A. C., Lim, K., Ren, S., Ma, P., & Zhou, D. (2026). Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study. British Journal of Clinical Pharmacology, 92(3), 980-996. https://doi.org/10.1002/bcp.70287

Vancouver

Zhao X, Ding J, Zhao J, Zhang L, Abegesah A, Zhang YQ, et al. Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study. British Journal of Clinical Pharmacology. 2026;92(3):980-996. doi:10.1002/bcp.70287

BibTeX
@article{Zhao2026,
  author = {Zhao, Xiaoying and Ding, Junjie and Zhao, Jiajia and Zhang, Ling and Abegesah, Aburough and Zhang, Yu-Qian and O'Brien, Cathy and Doherty, Gary J and Chen, Allen C and Lim, KyoungSoo and Ren, Song and Ma, Peiming and Zhou, Diansong},
  title = {Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {3},
  pages = {980--996},
  doi = {10.1002/bcp.70287}
}
Kostenlos starten →